Tag: GDP

Addressing Record Retention Failures During System Upgrades to Prevent Part 11 Findings In the ever-evolving landscape of pharmaceutical manufacturing, system upgrades can inadvertently lead to record retention failures, posing significant…

Addressing Record Retention Issues During the Validation Lifecycle to Prevent Part 11 Findings Record retention failures represent a critical threat in pharmaceutical manufacturing, particularly during the validation lifecycle of Electronic…

Strategies for Managing Uncontrolled Hybrid Paper-Electronic Workflows During Compliance Audits In the evolving landscape of pharmaceutical manufacturing, the integration of hybrid paper-electronic workflows has become a common practice. While these…

Addressing Electronic Signature Misuse Throughout the Validation Lifecycle In pharmaceutical manufacturing and quality control, the implementation of electronic signatures holds significant potential for operational efficiency and compliance. However, misuse of…

Addressing Uncontrolled Hybrid Paper-Electronic Workflows in Validation Lifecycle In today’s pharmaceutical landscape, hybrid paper-electronic workflows present significant challenges, particularly in maintaining compliance during the validation lifecycle. As organizations strive for…

Addressing Weaknesses in System Access Controls During the Validation Lifecycle In the fast-paced pharmaceutical environment, compliance with 21 CFR Part 11 is critical. However, weaknesses in system access controls can…

A Comprehensive Playbook for Addressing Record Retention Failures in Pharmaceutical Systems Record retention failures pose significant challenges during system operation, especially in relation to compliance with 21 CFR Part 11.…

Addressing Weak System Access Controls During Upgrades to Prevent Part 11 Findings The pharmaceutical industry is continuously advancing, particularly with the integration of electronic recordkeeping systems. However, these upgrades can…

Addressing Misuse of Electronic Signatures During System Upgrades: A Regulatory Playbook The use of electronic signatures (e-signatures) is a fundamental aspect of regulatory compliance in pharmaceutical manufacturing, especially during system…

Strategies for Managing Record Retention Failures During System Upgrades In the ever-evolving landscape of pharmaceutical manufacturing, the integrity of electronic records is paramount. Record retention failures during a system upgrade…

Managing ERES Controls Lapses During Compliance Audits: Your Playbook In an increasingly regulated environment, pharmaceutical manufacturers face mounting pressure to ensure robust compliance with Electronic Records and Electronic Signatures (ERES)…

Remediation for ERES Control Failures During System Operation In the evolving landscape of pharmaceutical manufacturing, the implementation of effective electronic records and electronic signatures (ERES) controls is critical. When ERES…